Baseline Blood CD8 + T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.
Hanneke KievitM Benthe Muntinghe-WagenaarWayel H AbdulahadAbraham RutgersLucie B M Hijmering-KappelleBirgitta I HiddingaJ Fred UbbelsRobin WijsmanMarcel J van der LeijJohan BijzetHarry J M GroenHuib A M KerstjensAnthonie J van der WekkenBart-Jan KroesenThijo Jeroen N HiltermannPublished in: Cancers (2024)
T cell activation potency, measured by intracellular cytokine production after ex vivo stimulation, is a potential biomarker to discriminate responders from non-responders to SBRT combined with ICI.